Hemant Surgical Industries Ltd

AI
Hemant Surgical Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Hemant Surgical Industries Ltd

₹ 590 -1.69%
16 Oct - close price
hemantsurgical.com BSE - SME: 543916
About

Incorporated in 1989, Hemant Surgical Industries Ltd is in the business of Medical Equipment & Supplies[1]

Key Points

Business Overview:[1][2]
HSIL is ISO 9001:2015, ISO 13485:2016 certified and CDSCO compliant company which deals in importing, manufacturing, and marketing medical disposable, surgical equipments and pharmaceutical products including
a) Supply of dialysis equipment, renal care, oxygen concentrators, air mattresses, ultrasound machines and digital thermometers, etc.
b) Design and manufacture of a range of nebulisers, which are
marketed under the company’s AERO brand
c) HSIL also refurbishes second-hand dialysis machines, manufactures
and supplies related accessories, dialysers and haemodialysis solutions

Website BSE
  • Market Cap ₹ 857 Cr.
  • Current Price ₹ 590
  • High / Low ₹ 679 / 215
  • Stock P/E 50.6
  • Book Value ₹ 105
  • Dividend Yield 0.00 %
  • ROCE 18.9 %
  • ROE 16.9 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 65.6% CAGR over last 5 years
  • Company's working capital requirements have reduced from 45.5 days to 24.0 days

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Debtor days have increased from 83.7 to 106 days.
  • Promoter holding has decreased over last 3 years: -20.7%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
51 58 48 58 49 58 64 167
47 52 44 51 45 52 57 151
Operating Profit 4 6 3 7 4 6 8 16
OPM % 8% 11% 7% 13% 7% 10% 12% 9%
1 1 3 2 2 3 2 3
Interest 1 1 1 0 1 1 2 2
Depreciation 0 0 1 1 1 1 1 1
Profit before tax 4 6 5 8 4 6 7 16
Tax % 36% 18% 17% 27% 29% 18% 25% 22%
2 5 4 6 3 5 5 13
EPS in Rs 2.89 6.93 3.75 5.63 3.05 4.74 4.15 9.84
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
51 56 56 60 101 109 106 107 231
48 53 53 57 95 98 95 97 208
Operating Profit 2 3 3 3 6 11 10 9 23
OPM % 4.9% 4.8% 4.7% 5% 6% 10% 10% 9% 10%
0 0 0 1 2 2 4 5 6
Interest 1 1 2 2 2 2 1 2 4
Depreciation 0 1 0 1 1 1 1 1 2
Profit before tax 1 1 1 1 6 10 13 11 24
Tax % 10% 8% 41% 9% 25% 24% 23% 23% 23%
1 1 0 1 5 8 10 8 18
EPS in Rs 3.13 3.77 1.67 4.53 15.37 9.95 9.39 7.79 13.98
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 31%
3 Years: 28%
TTM: 117%
Compounded Profit Growth
10 Years: %
5 Years: 66%
3 Years: 30%
TTM: 114%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 44%
1 Year: 97%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 17%
Last Year: 17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 2 2 2 2 2 8 10 10 13
Reserves 5 6 5 8 11 16 44 53 124
9 11 14 14 10 7 7 31 50
12 14 23 15 32 34 38 54 87
Total Liabilities 28 33 44 40 54 65 100 148 274
7 8 10 11 12 13 18 40 53
CWIP 0 0 0 0 0 0 0 12 0
Investments 0 0 1 0 1 0 5 0 0
21 25 33 29 42 51 77 96 220
Total Assets 28 33 44 40 54 65 100 148 274

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 0 2 -4 12 6 -4 5 -32
0 0 -2 -2 -0 -3 -12 -30 -10
0 0 2 5 -8 -1 21 22 76
Net Cash Flow 0 0 2 -2 4 3 5 -4 34
Free Cash Flow 0 0 -1 -7 12 2 -13 -31 -37
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 0% 0% 68% -127% 197% 84% -9% 78% -118%

Ratios

Standalone / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 35 36 35 26 56 58 75 70 106
Inventory Days 64 73 125 113 57 67 99 206 120
Days Payable 102 97 143 89 92 110 116 188 146
Cash Conversion Cycle -3 12 17 51 21 15 58 87 80
Working Capital Days 12 23 -28 41 -19 2 52 61 24
ROCE % 15% 12% 14% 32% 45% 30% 16% 19%

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Number of manufacturing and assembly units
count

Log in to view insights

Please log in to see hidden values.

Login
Number of permanent employees
count
Top 10 customers share of revenue
% of revenue
JMS products share of revenue
% of total revenue
Meditape share of revenue
% of revenue from operations
Number of international offices
count
Number of registered products
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026May 2026Sep 2026
73.56% 73.56% 73.56% 73.56% 58.90% 58.90% 52.83% 52.83%
0.03% 0.00% 0.00% 0.39% 0.15% 0.15% 0.14% 0.00%
4.26% 1.97% 1.13% 1.11% 10.81% 10.73% 19.94% 19.94%
22.14% 24.47% 25.31% 24.93% 30.13% 30.21% 27.10% 27.23%
No. of Shareholders 7221,2291,2481,2297588419481,202

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings